Table 1.
Statistical analysis of S100A7 immunoreactivity and clinicopathological parameters
| Pathological parameters | S100A7 immunoreactivity | P value | |
|---|---|---|---|
| Negative (−) | Positive (+) | ||
| n = 103 | n = 47 | ||
| Age, years | 56.6 ± 1.3 | 53.4 ± 1.9 | 0.149 |
| Menopausal status | |||
| Premenopausal | 37 (24.7%) | 22 (14.7%) | 0.213 |
| Postmenopausal | 66 (44.0%) | 25 (16.7%) | |
| Stage | |||
| I | 58 (39.2%) | 18 (12.2%) | 0.016 |
| II | 35 (23.6%) | 16 (10.8%) | |
| III | 9 (6.1%) | 12 (8.1%) | |
| Estrogen receptor status | |||
| Positive | 90 (60.8%) | 31 (20.9%) | 0.0012 |
| Negative | 11 (7.4%) | 16 (10.8%) | |
| Progesterone receptor status | |||
| Positive | 64 (43.2%) | 16 (10.8%) | 0.0013 |
| Negative | 37 (25.0%) | 31 (20.9%) | |
| HER2/neu status | |||
| Positive | 9 (6.1%) | 7 (4.7%) | 0.272 |
| Negative | 92 (62.2%) | 40 (27.0%) | |
| Ki-67 LI | 12.1 ± 1.2 | 21.3 ± 1.7 | <0.0001 |
| Histological grade | |||
| 1, 2 (well, moderate) | 79 (54.1%) | 21 (14.4%) | 0.027 |
| 3 (poor) | 28 (19.2%) | 18 (12.3%) | |
| Lymph node metastasis | |||
| Positive | 27 (18.2%) | 21 (14.2%) | 0.038 |
| Negative | 74 (50.0%) | 26 (17.6%) | |
HER2 Human epidermal growth factor receptor 2, LI Labeling index
P values (P < 0.05) were determined by analysis of variance and Fisher’s exact test
Significant P values (P < 0.05) were indicated in bold